Thermo Fisher Scientific has launched the Oncomine Childhood Cancer Research Assay, a next-generation sequencing panel developed in collaboration with Children’s Hospital Los Angeles that specifically targets mutations associated with pediatric and young adult cancers.

“The Oncomine Childhood Cancer Research Assay is of particular importance because it is the first designed for all forms of childhood cancers that simultaneously detects RNA gene fusions and DNA mutations, both of which are critical in childhood cancer,” said Timothy J. Triche, co-director at the Center for Personalized Medicine, Children’s Hospital Los Angeles. “I am also very excited by the International Childhood Oncology Network, which will allow us and its members to collect data and share our experience in an effort to drive clinical research in childhood cancer.”

Specifically, the assay combines specific mutations, gene amplification, and fusions across 203 genes representing multiple gene classes, and 1,700 fusion transcripts in two DNA and two RNA pools.

The assay is designed to integrate with the Ion Chef system for automated library preparation and amplification, as well as the Ion GeneStudio S5 system and Ion Reporter for bioinformatics and reporting.